Loading...

Webster Cavenee

TitleEmeritus Professor
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #0660
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Benitez JA, Ma J, D'Antonio M, Boyer A, Camargo MF, Zanca C, Kelly S, Khodadadi-Jamayran A, Jameson NM, Andersen M, Miletic H, Saberi S, Frazer KA, Cavenee W, Furnari FB. Publisher Correction: PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nat Commun. 2018 May 25; 9:16217. PMID: 29799523.
      View in: PubMed
    2. Talukdar S, Pradhan AK, Bhoopathi P, Shen XN, August LA, Windle JJ, Sarkar D, Furnari FB, Cavenee W, Das SK, Emdad L, Fisher PB. MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells. Proc Natl Acad Sci U S A. 2018 May 14. PMID: 29760085.
      View in: PubMed
    3. Benitez JA, Zanca C, Ma J, Cavenee W, Furnari FB. Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts. J Vis Exp. 2018 04 26; (134). PMID: 29757276.
      View in: PubMed
    4. Sun L, Yu S, Xu H, Zheng Y, Lin J, Wu M, Wang J, Wang A, Lan Q, Furnari F, Cavenee W, Purow B, Li M. FHL2 interacts with EGFR to promote glioblastoma growth. Oncogene. 2018 Mar; 37(10):1386-1398. PMID: 29321665.
      View in: PubMed
    5. Newman JP, Wang GY, Arima K, Guan SP, Waters MR, Cavenee W, Pan E, Aliwarga E, Chong ST, Kok CYL, Endaya BB, Habib AA, Horibe T, Ng WH, Ho IAW, Hui KM, Kordula T, Lam PYP. Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme. Nat Commun. 2017 Dec 04; 8(1):1913. PMID: 29203859.
      View in: PubMed
    6. Teixeira AA, Marchiò S, Dias-Neto E, Nunes DN, da Silva IT, Chackerian B, Barry M, Lauer RC, Giordano RJ, Sidman RL, Wheeler CM, Cavenee W, Pasqualini R, Arap W. Going viral? Linking the etiology of human prostate cancer to the PCA3 long noncoding RNA and oncogenic viruses. EMBO Mol Med. 2017 Oct; 9(10):1327-1330. PMID: 28751581.
      View in: PubMed
    7. Alexander BM, Ba S, Berger MS, Berry DA, Cavenee W, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clin Cancer Res. 2018 Feb 15; 24(4):737-743. PMID: 28814435.
      View in: PubMed
    8. Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, Wu S, Yang H, Wykosky J, Frazer KA, Verkhusha VV, Isaguliants MG, Weiss WA, Gahman TC, Shiau AK, Chen CC, Mischel PS, Cavenee W, Furnari FB. Glioblastoma cellular cross-talk converges on NF-?B to attenuate EGFR inhibitor sensitivity. Genes Dev. 2017 Jul 19. PMID: 28724615.
      View in: PubMed
    9. Cai J, Lin Y, Zhang H, Liang J, Tan Y, Cavenee W, Yan G. Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. Proc Natl Acad Sci U S A. 2017 06 27; 114(26):6812-6817. PMID: 28607091.
      View in: PubMed
    10. Benitez JA, Ma J, D'Antonio M, Boyer A, Camargo MF, Zanca C, Kelly S, Khodadadi-Jamayran A, Jameson NM, Andersen M, Miletic H, Saberi S, Frazer KA, Cavenee W, Furnari FB. PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nat Commun. 2017 May 12; 8:15223. PMID: 28497778.
      View in: PubMed
    11. Liu F, Mischel PS, Cavenee W. Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling. NPJ Precis Oncol. 2017; 1(1):1. PMID: 29872691.
      View in: PubMed
    12. Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, Kornblum HI, Taylor MD, Kaushal S, Cavenee W, Wechsler-Reya R, Furnari FB, Vandenberg SR, Rao PN, Wahl GM, Bafna V, Mischel PS. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature. 2017 03 02; 543(7643):122-125. PMID: 28178237.
      View in: PubMed
    13. Kegelman TP, Wu B, Das SK, Talukdar S, Beckta JM, Hu B, Emdad L, Valerie K, Sarkar D, Furnari FB, Cavenee W, Wei J, Purves A, De SK, Pellecchia M, Fisher PB. Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin. Proc Natl Acad Sci U S A. 2017 01 10; 114(2):370-375. PMID: 28011764.
      View in: PubMed
    14. Chou ST, Patil R, Galstyan A, Gangalum PR, Cavenee W, Furnari FB, Ljubimov VA, Chesnokova A, Kramerov AA, Ding H, Falahatian V, Mashouf L, Fox I, Black KL, Holler E, Ljubimov AV, Ljubimova JY. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. J Control Release. 2016 Dec 28; 244(Pt A):14-23. PMID: 27825958.
      View in: PubMed
    15. Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, Jenkins D, Martini M, Armando AM, Quehenberger O, Cloughesy TF, Furnari FB, Cavenee W, Tontonoz P, Gahman TC, Shiau AK, Cravatt BF, Mischel PS. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. 2016 Nov 14; 30(5):683-693. PMID: 27746144.
      View in: PubMed
    16. Masui K, Shibata N, Cavenee W, Mischel PS. mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling. Bioessays. 2016 09; 38(9):839-44. PMID: 27427440.
      View in: PubMed
    17. Masui K, Cavenee W, Mischel PS. Cancer metabolism as a central driving force of glioma pathogenesis. Brain Tumor Pathol. 2016 Jul; 33(3):161-8. PMID: 27295313.
      View in: PubMed
    18. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun; 131(6):803-20. PMID: 27157931.
      View in: PubMed
    19. Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, Li X, Bonetti B, Chopra R, James CD, Cavenee W, Cloughesy TF, Mischel PS, Heath JR, Gini B. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell. 2016 Apr 11; 29(4):563-573. PMID: 27070703.
      View in: PubMed
    20. Masui K, Cavenee W, Mischel PS. mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment. Brain Pathol. 2015 Nov; 25(6):755-9. PMID: 26526943; PMCID: PMC4636016 [Available on 11/01/16].
    21. Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, Barr CL, Furnari FB, Cloughesy TF, Yong WH, Gahman TC, Shiau AK, Cavenee W, Ren B, Mischel PS. EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Mol Cell. 2015 Oct 15; 60(2):307-18. PMID: 26455392; PMCID: PMC4609298 [Available on 10/15/16].
    22. Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee W, Mischel PS. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proc Natl Acad Sci U S A. 2015 Jul 28; 112(30):9406-11. PMID: 26170313; PMCID: PMC4522814.
    23. Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee W, Dias-Neto E, Pasqualini R, Arap W. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):8403-8. PMID: 26080435; PMCID: PMC4500257.
    24. Shen Y, Li J, Nitta M, Futalan D, Steed T, Treiber JM, Taich Z, Stevens D, Wykosky J, Chen HZ, Carter BS, Becher OJ, Kennedy R, Esashi F, Sarkaria JN, Furnari FB, Cavenee W, Desai A, Chen CC. Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. Oncotarget. 2015 May 20; 6(14):11751-67. PMID: 26059434.
      View in: PubMed
    25. Chua CY, Liu Y, Granberg KJ, Hu L, Haapasalo H, Annala MJ, Cogdell DE, Verploegen M, Moore LM, Fuller GN, Nykter M, Cavenee W, Zhang W. IGFBP2 potentiates nuclear EGFR-STAT3 signaling. Oncogene. 2016 Feb 11; 35(6):738-47. PMID: 25893308; PMCID: PMC4615268.
    26. Furnari FB, Cloughesy TF, Cavenee W, Mischel PS. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer. 2015 May; 15(5):302-10. PMID: 25855404; PMCID: PMC4875778.
    27. Chen K, Yang D, Li X, Sun B, Song F, Cao W, Brat DJ, Gao Z, Li H, Liang H, Zhao Y, Zheng H, Li M, Buckner J, Patterson SD, Ye X, Reinhard C, Bhathena A, Joshi D, Mischel PS, Croce CM, Wang YM, Raghavakaimal S, Li H, Lu X, Pan Y, Chang H, Ba S, Luo L, Cavenee W, Zhang W, Hao X. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci U S A. 2015 Jan 27; 112(4):1107-12. PMID: 25583476; PMCID: PMC4313862.
    28. Wu SH, Bi JF, Cloughesy T, Cavenee W, Mischel PS. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biol Med. 2014 Dec; 11(4):255-63. PMID: 25610711; PMCID: PMC4296088.
    29. Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee W, Furnari FB. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Res. 2015 Jan 15; 75(2):394-404. PMID: 25432173; PMCID: PMC4297573.
    30. Hu J, Muller KA, Furnari FB, Cavenee W, VandenBerg SR, Gonias SL. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. Oncogene. 2015 Jul 30; 34(31):4078-88. PMID: 25347738; PMCID: PMC4411189.
    31. Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, Kim SH, Minata M, Nakano I, Grandis JR, McLendon RE, Bigner DD, Lin HK, Furnari FB, Cavenee W, Hu B, Yan H, Cheng SY. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest. 2014 Sep; 124(9):3741-56. PMID: 25061874; PMCID: PMC4151226.
    32. Masui K, Cavenee W, Mischel PS. mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab. 2014 Jul; 25(7):364-73. PMID: 24856037; PMCID: PMC4077930.
    33. Li J, Zhu S, Kozono D, Ng K, Futalan D, Shen Y, Akers JC, Steed T, Kushwaha D, Schlabach M, Carter BS, Kwon CH, Furnari F, Cavenee W, Elledge S, Chen CC. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget. 2014 Feb 28; 5(4):882-93. PMID: 24658464; PMCID: PMC4011590.
    34. Masui K, Cavenee W, Mischel PS. mTORC2 dictates Warburg effect and drug resistance. Cell Cycle. 2014; 13(7):1053-4. PMID: 24583874; PMCID: PMC4013152.
    35. Kawashima N, Qu H, Lobaton M, Zhu Z, Sollogoub M, Cavenee W, Handa K, Hakomori SI, Zhang Y. Efficient synthesis of chloro-derivatives of sialosyllactosylceramide, and their enhanced inhibitory effect on epidermal growth factor receptor activation. Oncol Lett. 2014 Apr; 7(4):933-940. PMID: 24944646.
      View in: PubMed
    36. Gomez GG, Volinia S, Croce CM, Zanca C, Li M, Emnett R, Gutmann DH, Brennan CW, Furnari FB, Cavenee W. Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer Res. 2014 Mar 01; 74(5):1429-39. PMID: 24436148; PMCID: PMC3947420.
    37. Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, Nelson SF, Cloughesy TF, James CD, Rao PN, Kornblum HI, Heath JR, Cavenee W, Furnari FB, Mischel PS. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014 Jan 03; 343(6166):72-6. PMID: 24310612; PMCID: PMC4049335.
    38. Gomez GG, Wykosky J, Zanca C, Furnari FB, Cavenee W. Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biol Med. 2013 Dec; 10(4):192-205. PMID: 24349829; PMCID: PMC3860350.
    39. Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, Mellinghoff IK, Cavenee W, Shaw RJ, Mischel PS. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013 Nov 05; 18(5):726-39. PMID: 24140020; PMCID: PMC3840163.
    40. Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee W, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PS. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin Cancer Res. 2013 Oct 15; 19(20):5722-32. PMID: 24030701; PMCID: PMC3815450.
    41. Cloughesy TF, Cavenee W, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol. 2014; 9:1-25. PMID: 23937436.
      View in: PubMed
    42. Feng H, Hu B, Vuori K, Sarkaria JN, Furnari FB, Cavenee W, Cheng SY. EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. Oncogene. 2014 May 08; 33(19):2504-12. PMID: 23728337; PMCID: PMC3883905.
    43. Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, Kurdistani SK, Eskin A, Nelson SF, Yong WH, Cavenee W, Cloughesy TF, Christofk HR, Black DL, Mischel PS. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 2013 Jun 04; 17(6):1000-8. PMID: 23707073; PMCID: PMC3679227.
    44. Iwanami A, Cloughesy TF, Cavenee W, Mischel PS. Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell Cycle. 2013 May 15; 12(10):1473-4. PMID: 23624839; PMCID: PMC3680520.
    45. Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee W, Bensinger SJ, Mischel PS. De-repression of PDGFRß transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 2013 May; 3(5):534-47. PMID: 23533263; PMCID: PMC3651754.
    46. Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee W. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis. 2013 Apr; 34(4):725-38. PMID: 23455378; PMCID: PMC3616676.
    47. Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee W, Cloughesy TF, Furnari FB, Nakamura M, Toyama Y, Okano H, Mischel PS. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proc Natl Acad Sci U S A. 2013 Mar 12; 110(11):4339-44. PMID: 23440206; PMCID: PMC3600508.
    48. Read RD, Fenton TR, Gomez GG, Wykosky J, Vandenberg SR, Babic I, Iwanami A, Yang H, Cavenee W, Mischel PS, Furnari FB, Thomas JB. A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma. PLoS Genet. 2013; 9(2):e1003253. PMID: 23459592; PMCID: PMC3573097.
    49. Cavenee W. Genetic driver events in premalignancy: LOH validated for marking the risk of oral cancer. Cancer Prev Res (Phila). 2012 Sep; 5(9):1073-4. PMID: 22911109.
      View in: PubMed
    50. Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, Vandenberg SR, Zhou H, Marie SK, Mischel PS, Cavenee W, Furnari FB. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A. 2012 Aug 28; 109(35):14164-9. PMID: 22891331; PMCID: PMC3435194.
    51. Latha K, Li M, Chumbalkar V, Gururaj A, Hwang Y, Dakeng S, Sawaya R, Aldape K, Cavenee W, Bogler O, Furnari FB. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter. Int J Cancer. 2013 Feb 01; 132(3):509-20. PMID: 22729867; PMCID: PMC3802533.
    52. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee W, Depinho RA, Chin L, Hahn WC. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012 Apr 15; 26(8):756-84. PMID: 22508724; PMCID: PMC3337451.
    53. Taylor TE, Furnari FB, Cavenee W. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets. 2012 Mar; 12(3):197-209. PMID: 22268382; PMCID: PMC3464093.
    54. Feng H, Hu B, Jarzynka MJ, Li Y, Keezer S, Johns TG, Tang CK, Hamilton RL, Vuori K, Nishikawa R, Sarkaria JN, Fenton T, Cheng T, Furnari FB, Cavenee W, Cheng SY. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):3018-23. PMID: 22323579; PMCID: PMC3286964.
    55. Li M, Mukasa A, Inda MM, Zhang J, Chin L, Cavenee W, Furnari F. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. J Exp Med. 2011 Dec 19; 208(13):2657-73. PMID: 22162832; PMCID: PMC3244036.
    56. Bonavia R, Inda MM, Vandenberg S, Cheng SY, Nagane M, Hadwiger P, Tan P, Sah DW, Cavenee W, Furnari FB. EGFRvIII promotes glioma angiogenesis and growth through the NF-?B, interleukin-8 pathway. Oncogene. 2012 Sep 06; 31(36):4054-66. PMID: 22139077; PMCID: PMC3537826.
    57. Feng H, Hu B, Liu KW, Li Y, Lu X, Cheng T, Yiin JJ, Lu S, Keezer S, Fenton T, Furnari FB, Hamilton RL, Vuori K, Sarkaria JN, Nagane M, Nishikawa R, Cavenee W, Cheng SY. Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRa-stimulated glioma tumorigenesis in mice and humans. J Clin Invest. 2011 Dec; 121(12):4670-84. PMID: 22080864; PMCID: PMC3223070.
    58. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee W, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS. Oncogenic EGFR signaling activates an mTORC2-NF-?B pathway that promotes chemotherapy resistance. Cancer Discov. 2011 Nov; 1(6):524-38. PMID: 22145100; PMCID: PMC3229221.
    59. Hu J, Jo M, Cavenee W, Furnari F, VandenBerg SR, Gonias SL. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proc Natl Acad Sci U S A. 2011 Sep 20; 108(38):15984-9. PMID: 21896743; PMCID: PMC3179096.
    60. Cvrljevic AN, Akhavan D, Wu M, Martinello P, Furnari FB, Johnston AJ, Guo D, Pike L, Cavenee W, Scott AM, Mischel PS, Hoogenraad NJ, Johns TG. Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. J Cell Sci. 2011 Sep 01; 124(Pt 17):2938-50. PMID: 21878501; PMCID: PMC3706030.
    61. Wang Y, Huang JW, Li M, Cavenee W, Mitchell PS, Zhou X, Tewari M, Furnari FB, Taniguchi T. MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol Cancer Res. 2011 Aug; 9(8):1100-11. PMID: 21693595; PMCID: PMC3157593.
    62. Bonavia R, Inda MM, Cavenee W, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 2011 Jun 15; 71(12):4055-60. PMID: 21628493; PMCID: PMC3117065.
    63. Chumbalkar V, Latha K, Hwang Y, Maywald R, Hawley L, Sawaya R, Diao L, Baggerly K, Cavenee W, Furnari FB, Bogler O. Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ?EGFR. J Proteome Res. 2011 Mar 04; 10(3):1343-52. PMID: 21214269; PMCID: PMC3049961.
    64. Wykosky J, Fenton T, Furnari F, Cavenee W. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin J Cancer. 2011 Jan; 30(1):5-12. PMID: 21192840; PMCID: PMC3359794.
    65. Staquicini FI, Ozawa MG, Moya CA, Driessen WH, Barbu EM, Nishimori H, Soghomonyan S, Flores LG, Liang X, Paolillo V, Alauddin MM, Basilion JP, Furnari FB, Bogler O, Lang FF, Aldape KD, Fuller GN, Höök M, Gelovani JG, Sidman RL, Cavenee W, Pasqualini R, Arap W. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J Clin Invest. 2011 Jan; 121(1):161-73. PMID: 21183793; PMCID: PMC3007161.
    66. Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, Tan P, Depinho RA, Cavenee W, Furnari F. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010 Aug 15; 24(16):1731-45. PMID: 20713517; PMCID: PMC2922502.
    67. Huh SJ, Chen YL, Friedman SL, Liao J, Huang HJ, Cavenee W, Robertson GP. KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment. J Natl Cancer Inst. 2010 Aug 04; 102(15):1131-47. PMID: 20660366; PMCID: PMC2914760.
    68. Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, Zinn PO, Kushwaha D, Kesari S, Inda MM, Wykosky J, Furnari F, Hoadley KA, Chin L, DePinho RA, Cavenee W, D'Andrea A, Chen CC. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PLoS One. 2010 May 24; 5(5):e10767. PMID: 20532243; PMCID: PMC2879424.
    69. Wykosky J, Mukasa A, Furnari F, Cavenee W. Escape from targeted inhibition: the dark side of kinase inhibitor therapy. Cell Cycle. 2010 May; 9(9):1661-2. PMID: 20404502.
      View in: PubMed
    70. Huang PH, Miraldi ER, Xu AM, Kundukulam VA, Del Rosario AM, Flynn RA, Cavenee W, Furnari FB, White FM. Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. Mol Biosyst. 2010 Jul; 6(7):1227-37. PMID: 20461251; PMCID: PMC3291333.
    71. Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee W, Furnari F. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci U S A. 2010 Feb 09; 107(6):2616-21. PMID: 20133782; PMCID: PMC2823874.
    72. Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, Seligson D, Chakravari A, Lee FY, Weinmann R, Cloughesy TF, Nelson SF, Bergers G, Graeber T, Furnari FB, James CD, Cavenee W, Johns TG, Mischel PS. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res. 2009 Sep 01; 69(17):6889-98. PMID: 19690143; PMCID: PMC2770839.
    73. Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S, Hatanpaa KJ, Mickey B, Madden C, Maher E, Boothman DA, Furnari F, Cavenee W, Bachoo RM, Burma S. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res. 2009 May 15; 69(10):4252-9. PMID: 19435898; PMCID: PMC2694953.
    74. Garrett TP, Burgess AW, Gan HK, Luwor RB, Cartwright G, Walker F, Orchard SG, Clayton AH, Nice EC, Rothacker J, Catimel B, Cavenee W, Old LJ, Stockert E, Ritter G, Adams TE, Hoyne PA, Wittrup D, Chao G, Cochran JR, Luo C, Lou M, Huyton T, Xu Y, Fairlie WD, Yao S, Scott AM, Johns TG. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci U S A. 2009 Mar 31; 106(13):5082-7. PMID: 19289842; PMCID: PMC2656555.
    75. James CD, Cavenee W. Stem cells for treating glioblastoma: how close to reality? Neuro Oncol. 2009 Apr; 11(2):101. PMID: 19237733; PMCID: PMC2718980.
    76. Read RD, Cavenee W, Furnari FB, Thomas JB. A drosophila model for EGFR-Ras and PI3K-dependent human glioma. PLoS Genet. 2009 Feb; 5(2):e1000374. PMID: 19214224; PMCID: PMC2636203.
    77. Wiedemeyer R, Brennan C, Heffernan TP, Xiao Y, Mahoney J, Protopopov A, Zheng H, Bignell G, Furnari F, Cavenee W, Hahn WC, Ichimura K, Collins VP, Chu GC, Stratton MR, Ligon KL, Futreal PA, Chin L. Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell. 2008 Apr; 13(4):355-64. PMID: 18394558; PMCID: PMC2292238.
    78. Roeb W, Boyer A, Cavenee W, Arden KC. Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor. Cell Cycle. 2008 Apr 01; 7(7):837-41. PMID: 18414034.
      View in: PubMed
    79. Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, Cavenee W, Cloughesy TF, Mischel PS. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res. 2008 Jan 15; 14(2):488-93. PMID: 18223223.
      View in: PubMed
    80. Barrera LO, Li Z, Smith AD, Arden KC, Cavenee W, Zhang MQ, Green RD, Ren B. Genome-wide mapping and analysis of active promoters in mouse embryonic stem cells and adult organs. Genome Res. 2008 Jan; 18(1):46-59. PMID: 18042645; PMCID: PMC2134779.
    81. Roeb W, Boyer A, Cavenee W, Arden KC. PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1. Proc Natl Acad Sci U S A. 2007 Nov 13; 104(46):18085-90. PMID: 17986608; PMCID: PMC2084300.
    82. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee W. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007 Nov 01; 21(21):2683-710. PMID: 17974913.
      View in: PubMed
    83. Huang PH, Cavenee W, Furnari FB, White FM. Uncovering therapeutic targets for glioblastoma: a systems biology approach. Cell Cycle. 2007 Nov 15; 6(22):2750-4. PMID: 17986864.
      View in: PubMed
    84. Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee W, Furnari FB, White FM. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A. 2007 Jul 31; 104(31):12867-72. PMID: 17646646; PMCID: PMC1937558.
    85. Louis DN, Ohgaki H, Wiestler OD, Cavenee W, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007 Aug; 114(2):97-109. PMID: 17618441; PMCID: PMC1929165.
    86. Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee W, Scott AM, Furnari FB. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res. 2007 Mar 15; 13(6):1911-25. PMID: 17363548.
      View in: PubMed
    87. Nagane M, Cavenee W, Shiokawa Y. Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand. J Neurosurg. 2007 Mar; 106(3):407-16. PMID: 17367063.
      View in: PubMed
    88. Li D, Ji H, Zaghlul S, McNamara K, Liang MC, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Scott AM, Jungbluth AA, Cavenee W, Old LJ, Demetri GD, Wong KK. Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest. 2007 Feb; 117(2):346-52. PMID: 17256054; PMCID: PMC1770949.
    89. Finckenstein FG, Davicioni E, Osborn KG, Cavenee W, Arden KC, Anderson MJ. Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube. Transgenic Res. 2006 Oct; 15(5):595-614. PMID: 16952014.
      View in: PubMed
    90. Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee W, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 2006 Aug 15; 66(16):7864-9. PMID: 16912159.
      View in: PubMed
    91. Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee W, Furnari FB. PCAF modulates PTEN activity. J Biol Chem. 2006 Sep 08; 281(36):26562-8. PMID: 16829519.
      View in: PubMed
    92. Carrasco DR, Fenton T, Sukhdeo K, Protopopova M, Enos M, You MJ, Di Vizio D, Divicio D, Nogueira C, Stommel J, Pinkus GS, Fletcher C, Hornick JL, Cavenee W, Furnari FB, Depinho RA. The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell. 2006 May; 9(5):379-90. PMID: 16697958.
      View in: PubMed
    93. Wu AH, Xiao J, Anker L, Hall WA, Gregerson DS, Cavenee W, Chen W, Low WC. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol. 2006 Jan; 76(1):23-30. PMID: 16155724.
      View in: PubMed
    94. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee W, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005 Nov 10; 353(19):2012-24. PMID: 16282176.
      View in: PubMed
    95. Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee W, Scott AM, Johns TG. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res. 2005 Sep 01; 11(17):6390-9. PMID: 16144944.
      View in: PubMed
    96. Okumura K, Zhao M, DePinho RA, Furnari FB, Cavenee W. PTEN: a novel anti-oncogenic function independent of phosphatase activity. Cell Cycle. 2005 Apr; 4(4):540-2. PMID: 15753657.
      View in: PubMed
    97. Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee W. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci U S A. 2005 Feb 22; 102(8):2703-6. PMID: 15659546; PMCID: PMC549467.
    98. Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee W, Wang XF, Bigner DD, Friedman HS, Rich JN. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther. 2005 Jan; 4(1):101-12. PMID: 15657358.
      View in: PubMed
    99. Schmidt MH, Hoeller D, Yu J, Furnari FB, Cavenee W, Dikic I, Bögler O. Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex. Mol Cell Biol. 2004 Oct; 24(20):8981-93. PMID: 15456872; PMCID: PMC517880.
    100. Hosaka T, Biggs WH, Tieu D, Boyer AD, Varki NM, Cavenee W, Arden KC. Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc Natl Acad Sci U S A. 2004 Mar 02; 101(9):2975-80. PMID: 14978268; PMCID: PMC365730.
    101. Nishikawa R, Sugiyama T, Narita Y, Furnari F, Cavenee W, Matsutani M. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol. 2004; 21(2):53-6. PMID: 15700833.
      View in: PubMed
    102. Cavenee W. The recessive nature of dominance. Genes Chromosomes Cancer. 2003 Dec; 38(4):322-5. PMID: 14566850.
      View in: PubMed
    103. Brentani H, Caballero OL, Camargo AA, da Silva AM, da Silva WA, Dias Neto E, Grivet M, Gruber A, Guimaraes PE, Hide W, Iseli C, Jongeneel CV, Kelso J, Nagai MA, Ojopi EP, Osorio EC, Reis EM, Riggins GJ, Simpson AJ, de Souza S, Stevenson BJ, Strausberg RL, Tajara EH, Verjovski-Almeida S, Acencio ML, Bengtson MH, Bettoni F, Bodmer WF, Briones MR, Camargo LP, Cavenee W, Cerutti JM, Coelho Andrade LE, Costa dos Santos PC, Ramos Costa MC, da Silva IT, Estécio MR, Sa Ferreira K, Furnari FB, Faria M, Galante PA, Guimaraes GS, Holanda AJ, Kimura ET, Leerkes MR, Lu X, Maciel RM, Martins EA, Massirer KB, Melo AS, Mestriner CA, Miracca EC, Miranda LL, Nobrega FG, Oliveira PS, Paquola AC, Pandolfi JR, Campos Pardini MI, Passetti F, Quackenbush J, Schnabel B, Sogayar MC, Souza JE, Valentini SR, Zaiats AC, Amaral EJ, Arnaldi LA, de Araújo AG, de Bessa SA, Bicknell DC, Ribeiro de Camaro ME, Carraro DM, Carrer H, Carvalho AF, Colin C, Costa F, Curcio C, Guerreiro da Silva ID, Pereira da Silva N, Dellamano M, El-Dorry H, Espreafico EM, Scattone Ferreira AJ, Ayres Ferreira C, Fortes MA, Gama AH, Giannella-Neto D, Giannella ML, Giorgi RR, Goldman GH, Goldman MH, Hackel C, Ho PL, Kimura EM, Kowalski LP, Krieger JE, Leite LC, Lopes A, Luna AM, Mackay A, Mari SK, Marques AA, Martins WK, Montagnini A, Mourão Neto M, Nascimento AL, Neville AM, Nobrega MP, O'Hare MJ, Otsuka AY, Ruas de Melo AI, Paco-Larson ML, Guimarães Pereira G, Pereira da Silva N, Pesquero JB, Pessoa JG, Rahal P, Rainho CA, Rodrigues V, Rogatto SR, Romano CM, Romeiro JG, Rossi BM, Rusticci M, Guerra de Sá R, Sant' Anna SC, Sarmazo ML, Silva TC, Soares FA, Sonati Mde F, de Freitas Sousa J, Queiroz D, Valente V, Vettore AL, Villanova FE, Zago MA, Zalcberg H. The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci U S A. 2003 Nov 11; 100(23):13418-23. PMID: 14593198; PMCID: PMC263829.
    104. Hu B, Guo P, Fang Q, Tao HQ, Wang D, Nagane M, Huang HJ, Gunji Y, Nishikawa R, Alitalo K, Cavenee W, Cheng SY. Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A. 2003 Jul 22; 100(15):8904-9. PMID: 12861074; PMCID: PMC166411.
    105. Li Z, Van Calcar S, Qu C, Cavenee W, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A. 2003 Jul 08; 100(14):8164-9. PMID: 12808131; PMCID: PMC166200.
    106. Schmidt MH, Furnari FB, Cavenee W, Bögler O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc Natl Acad Sci U S A. 2003 May 27; 100(11):6505-10. PMID: 12734385; PMCID: PMC164476.
    107. Guo P, Hu B, Gu W, Xu L, Wang D, Huang HJ, Cavenee W, Cheng SY. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol. 2003 Apr; 162(4):1083-93. PMID: 12651601; PMCID: PMC1851242.
    108. Cavenee W. Preparing for serendipity. Cancer Biol Ther. 2003 Mar-Apr; 2(2):213-5. PMID: 12750567.
      View in: PubMed
    109. Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ, Ritter G, Cohen L, Scanlan MJ, Cavenee W, Old LJ, Cavanee WK. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A. 2003 Jan 21; 100(2):639-44. PMID: 12515857; PMCID: PMC141049.
    110. Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee W. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res. 2002 Nov 15; 62(22):6764-9. PMID: 12438278.
      View in: PubMed
    111. Cavenee W. Muscling in on rhabdomyosarcoma. Nat Med. 2002 Nov; 8(11):1200-1. PMID: 12411939.
      View in: PubMed
    112. Nakae J, Biggs WH, Kitamura T, Cavenee W, Wright CV, Arden KC, Accili D. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet. 2002 Oct; 32(2):245-53. PMID: 12219087.
      View in: PubMed
    113. De Smet C, Nishimori H, Furnari FB, Bögler O, Huang HJ, Cavenee W. A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression. J Neurochem. 2002 May; 81(3):575-88. PMID: 12065666.
      View in: PubMed
    114. Cavenee W. Genetics and new approaches to cancer therapy. Carcinogenesis. 2002 May; 23(5):683-6. PMID: 12016138.
      View in: PubMed
    115. Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee W, Smyth FE, Hall CM, Watson N, Nice EC, Gullick WJ, Old LJ, Burgess AW, Scott AM. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer. 2002 Mar 20; 98(3):398-408. PMID: 11920591.
      View in: PubMed
    116. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee W. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002 Mar; 61(3):215-25; discussion 226-9. PMID: 11895036.
      View in: PubMed
    117. Costello JF, Plass C, Cavenee W. Restriction landmark genome scanning. Methods Mol Biol. 2002; 200:53-70. PMID: 11951655.
      View in: PubMed
    118. Steinbach JP, Supra P, Huang HJ, Cavenee W, Weller M. CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. Brain Pathol. 2002 Jan; 12(1):12-20. PMID: 11770895.
      View in: PubMed
    119. Klingler-Hoffmann M, Fodero-Tavoletti MT, Mishima K, Narita Y, Cavenee W, Furnari FB, Huang HJ, Tiganis T. The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor. J Biol Chem. 2001 Dec 07; 276(49):46313-8. PMID: 11514572.
      View in: PubMed
    120. Guo P, Xu L, Pan S, Brekken RA, Yang ST, Whitaker GB, Nagane M, Thorpe PE, Rosenbaum JS, Su Huang HJ, Cavenee W, Cheng SY. Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. Cancer Res. 2001 Dec 01; 61(23):8569-77. PMID: 11731444.
      View in: PubMed
    121. Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee W, Huang HJ. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg. 2001 Sep; 95(3):472-9. PMID: 11565870.
      View in: PubMed
    122. Chuenkova MV, Furnari FB, Cavenee W, Pereira MA. Trypanosoma cruzi trans-sialidase: a potent and specific survival factor for human Schwann cells by means of phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci U S A. 2001 Aug 14; 98(17):9936-41. PMID: 11481434; PMCID: PMC55556.
    123. Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee W, Ritter G, Old LJ, Burgess AW, Scott AM. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res. 2001 Jul 15; 61(14):5355-61. PMID: 11454674.
      View in: PubMed
    124. Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, Huang HJ, Cavenee W. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 2001 Jul 15; 61(14):5349-54. PMID: 11454673.
      View in: PubMed
    125. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee W, DePinho RA. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001 Jun 01; 15(11):1311-33. PMID: 11390353.
      View in: PubMed
    126. Biggs WH, Cavenee W, Arden KC. Identification and characterization of members of the FKHR (FOX O) subclass of winged-helix transcription factors in the mouse. Mamm Genome. 2001 Jun; 12(6):416-25. PMID: 11353388.
      View in: PubMed
    127. Nagane M, Huang HJ, Cavenee W. The potential of TRAIL for cancer chemotherapy. Apoptosis. 2001 Jun; 6(3):191-7. PMID: 11388668.
      View in: PubMed
    128. Fan X, Furnari FB, Cavenee W, Castresana JS. Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells. Int J Oncol. 2001 May; 18(5):1023-6. PMID: 11295051.
      View in: PubMed
    129. Anderson MJ, Shelton GD, Cavenee W, Arden KC. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc Natl Acad Sci U S A. 2001 Feb 13; 98(4):1589-94. PMID: 11171995; PMCID: PMC29301.
    130. Cardó-Vila M, Arden KC, Cavenee W, Pasqualini R, Arap W. Is annexin 7 a tumor suppressor gene in prostate cancer? Pharmacogenomics J. 2001; 1(2):92-4. PMID: 11911446.
      View in: PubMed
    131. Nagane M, Lin H, Cavenee W, Huang HJ. Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett. 2001 Jan; 162 Suppl:S17-S21. PMID: 11164186.
      View in: PubMed
    132. Mishima K, Mazar AP, Gown A, Skelly M, Ji XD, Wang XD, Jones TR, Cavenee W, Huang HJ. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci U S A. 2000 Jul 18; 97(15):8484-9. PMID: 10890917; PMCID: PMC26974.
    133. Reiss K, Wang JY, Romano G, Furnari FB, Cavenee W, Morrione A, Tu X, Baserga R. IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene. 2000 May 18; 19(22):2687-94. PMID: 10851068.
      View in: PubMed
    134. Amler LC, Bauer A, Corvi R, Dihlmann S, Praml C, Cavenee W, Schwab M, Hampton GM. Identification and characterization of novel genes located at the t(1;15)(p36.2;q24) translocation breakpoint in the neuroblastoma cell line NGP. Genomics. 2000 Mar 01; 64(2):195-202. PMID: 10729226.
      View in: PubMed
    135. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee W, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 2000 Feb 15; 60(4):847-53. PMID: 10706092.
      View in: PubMed
    136. Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee W, Plass C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000 Feb; 24(2):132-8. PMID: 10655057.
      View in: PubMed
    137. Costello JF, Plass C, Cavenee W. Aberrant methylation of genes in low-grade astrocytomas. Brain Tumor Pathol. 2000; 17(2):49-56. PMID: 11210171.
      View in: PubMed
    138. Bögler O, Furnari FB, Kindler-Roehrborn A, Sykes VW, Yung R, Huang HJ, Cavenee W. SETA: a novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes. Neuro Oncol. 2000 01; 2(1):6-15. PMID: 11302255; PMCID: PMC1920697.
    139. Nishimori H, Nishikawa R, Fujimaki T, Nakagomi T, Matsutani M, Huang HJ, Cavenee W. Analysis of the p300/CBP-Associated Factor (PCAF) gene in astrocytic tumors. J Neurooncol. 2000; 46(1):17-22. PMID: 10896202.
      View in: PubMed
    140. Valter MM, Hügel A, Huang HJ, Cavenee W, Wiestler OD, Pietsch T, Wernert N. Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis. Cancer Res. 1999 Nov 01; 59(21):5608-14. PMID: 10554042.
      View in: PubMed
    141. Knudsen KE, Weber E, Arden KC, Cavenee W, Feramisco JR, Knudsen ES. The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene. 1999 Sep 16; 18(37):5239-45. PMID: 10498874.
      View in: PubMed
    142. Robertson GP, Herbst RA, Nagane M, Huang HJ, Cavenee W. The chromosome 10 monosomy common in human melanomas results from loss of two separate tumor suppressor loci. Cancer Res. 1999 Aug 01; 59(15):3596-601. PMID: 10446968.
      View in: PubMed
    143. Wick W, Furnari FB, Naumann U, Cavenee W, Weller M. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene. 1999 Jul 08; 18(27):3936-43. PMID: 10435616.
      View in: PubMed
    144. Robertson GP, Huang HJ, Cavenee W. Identification and validation of tumor suppressor genes. Mol Cell Biol Res Commun. 1999 Jul; 2(1):1-10. PMID: 10527883.
      View in: PubMed
    145. Biggs WH, Meisenhelder J, Hunter T, Cavenee W, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A. 1999 Jun 22; 96(13):7421-6. PMID: 10377430; PMCID: PMC22101.
    146. Smiraglia DJ, Frühwald MC, Costello JF, McCormick SP, Dai Z, Peltomäki P, O'Dorisio MS, Cavenee W, Plass C. A new tool for the rapid cloning of amplified and hypermethylated human DNA sequences from restriction landmark genome scanning gels. Genomics. 1999 Jun 15; 58(3):254-62. PMID: 10373323.
      View in: PubMed
    147. Knudsen KE, Cavenee W, Arden KC. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res. 1999 May 15; 59(10):2297-301. PMID: 10344732.
      View in: PubMed
    148. Wang D, Huang HJ, Kazlauskas A, Cavenee W. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res. 1999 Apr 01; 59(7):1464-72. PMID: 10197615.
      View in: PubMed
    149. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee W, Baylin SB, Graff JR. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 1999 Feb 15; 59(4):798-802. PMID: 10029065.
      View in: PubMed
    150. Bögler O, Nagane M, Gillis J, Huang HJ, Cavenee W. Malignant transformation of p53-deficient astrocytes is modulated by environmental cues in vitro. Cell Growth Differ. 1999 Feb; 10(2):73-86. PMID: 10074901.
      View in: PubMed
    151. Nagane M, Huang HJ, Cavenee W. Causes of drug resistance and novel therapeutic opportunities for the treatment of glioblastoma. Drug Resist Updat. 1999 Feb; 2(1):30-37. PMID: 11504467.
      View in: PubMed
    152. Furnari FB, Huang HJ, Cavenee W. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res. 1998 Nov 15; 58(22):5002-8. PMID: 9823298.
      View in: PubMed
    153. Nishikawa R, Cheng SY, Nagashima R, Huang HJ, Cavenee W, Matsutani M. Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol. 1998 Nov; 96(5):453-62. PMID: 9829808.
      View in: PubMed
    154. Roberts WG, Delaat J, Nagane M, Huang S, Cavenee W, Palade GE. Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol. 1998 Oct; 153(4):1239-48. PMID: 9777955; PMCID: PMC1853053.
    155. Knudsen KE, Arden KC, Cavenee W. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem. 1998 Aug 07; 273(32):20213-22. PMID: 9685369.
      View in: PubMed
    156. Robertson GP, Furnari FB, Miele ME, Glendening MJ, Welch DR, Fountain JW, Lugo TG, Huang HJ, Cavenee W. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci U S A. 1998 Aug 04; 95(16):9418-23. PMID: 9689095; PMCID: PMC21353.
    157. Carethers JM, Furnari FB, Zigman AF, Lavine JE, Jones MC, Graham GE, Teebi AS, Huang HJ, Ha HT, Chauhan DP, Chang CL, Cavenee W, Boland CR. Absence of PTEN/MMAC1 germ-line mutations in sporadic Bannayan-Riley-Ruvalcaba syndrome. Cancer Res. 1998 Jul 01; 58(13):2724-6. PMID: 9661881.
      View in: PubMed
    158. Nagane M, Levitzki A, Gazit A, Cavenee W, Huang HJ. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A. 1998 May 12; 95(10):5724-9. PMID: 9576951; PMCID: PMC20446.
    159. Anderson MJ, Viars CS, Czekay S, Cavenee W, Arden KC. Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics. 1998 Jan 15; 47(2):187-99. PMID: 9479491.
      View in: PubMed
    160. Furnari FB, Lin H, Huang HS, Cavenee W. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci U S A. 1997 Nov 11; 94(23):12479-84. PMID: 9356475; PMCID: PMC25009.
    161. Cheng SY, Nagane M, Huang HS, Cavenee W. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci U S A. 1997 Oct 28; 94(22):12081-7. PMID: 9342366; PMCID: PMC23709.
    162. Arap W, Knudsen E, Sewell DA, Sidransky D, Wang JY, Huang HJ, Cavenee W. Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway. Oncogene. 1997 Oct 23; 15(17):2013-20. PMID: 9366518.
      View in: PubMed
    163. Larson AA, Liao SY, Stanbridge EJ, Cavenee W, Hampton GM. Genetic alterations accumulate during cervical tumorigenesis and indicate a common origin for multifocal lesions. Cancer Res. 1997 Oct 01; 57(19):4171-6. PMID: 9331069.
      View in: PubMed
    164. Larson AA, Kern S, Curtiss S, Gordon R, Cavenee W, Hampton GM. High resolution analysis of chromosome 3p alterations in cervical carcinoma. Cancer Res. 1997 Sep 15; 57(18):4082-90. PMID: 9307297.
      View in: PubMed
    165. Plass C, Weichenhan D, Catanese J, Costello JF, Yu F, Yu L, Smiraglia D, Cavenee W, Caligiuri MA, deJong P, Held WA. An arrayed human not I-EcoRV boundary library as a tool for RLGS spot analysis. DNA Res. 1997 Jun 30; 4(3):253-5. PMID: 9330914.
      View in: PubMed
    166. Herbst RA, Gutzmer R, Matiaske F, Mommert S, Kapp A, Weiss J, Arden KC, Cavenee W. Further evidence for ultraviolet light induction of CDKN2 (p16INK4) mutations in sporadic melanoma in vivo. J Invest Dermatol. 1997 Jun; 108(6):950. PMID: 9182829.
      View in: PubMed
    167. Nagane M, Huang HJ, Cavenee W. Advances in the molecular genetics of gliomas. Curr Opin Oncol. 1997 May; 9(3):215-22. PMID: 9229142.
      View in: PubMed
    168. Costello JF, Plass C, Arap W, Chapman VM, Held WA, Berger MS, Su Huang HJ, Cavenee W. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res. 1997 Apr 01; 57(7):1250-4. PMID: 9102208.
      View in: PubMed
    169. Arap W, Knudsen ES, Wang JY, Cavenee W, Huang HJ. Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma. Oncogene. 1997 Feb 06; 14(5):603-9. PMID: 9053859.
      View in: PubMed
    170. Pietsch T, Valter MM, Wolf HK, von Deimling A, Huang HJ, Cavenee W, Wiestler OD. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol. 1997 Feb; 93(2):109-17. PMID: 9039457.
      View in: PubMed
    171. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee W. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem. 1997 Jan 31; 272(5):2927-35. PMID: 9006938.
      View in: PubMed
    172. Besnard-Guérin C, Winqvist R, Newsham I, Cavenee W. Population variation at the polymorphic ApaLI restriction enzyme site in intron 5 of the WT1 gene. Clin Genet. 1996 Dec; 50(6):555-7. PMID: 9147899.
      View in: PubMed
    173. Nagane M, Coufal F, Lin H, Bögler O, Cavenee W, Huang HJ. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 1996 Nov 01; 56(21):5079-86. PMID: 8895767.
      View in: PubMed
    174. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee W, Huang HS. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem. 1996 Oct 11; 271(41):25639-45. PMID: 8810340.
      View in: PubMed
    175. Han Y, Caday CG, Nanda A, Cavenee W, Huang HJ. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res. 1996 Sep 01; 56(17):3859-61. PMID: 8752145.
      View in: PubMed
    176. Wasserman LM, Newsham I, Huang HJ, Cavenee W. cAMP effects on myogenic gene expression in rhabdomyosarcoma cells. Exp Cell Res. 1996 Aug 25; 227(1):55-62. PMID: 8806451.
      View in: PubMed
    177. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC, Arap W, Huang CM, Cavenee W. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A. 1996 Aug 06; 93(16):8502-7. PMID: 8710899; PMCID: PMC38701.
    178. Arden KC, Anderson MJ, Finckenstein FG, Czekay S, Cavenee W. Detection of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma using the reverse transcriptase-polymerase chain reaction. Genes Chromosomes Cancer. 1996 Aug; 16(4):254-60. PMID: 8875239.
      View in: PubMed
    179. Hampton GM, Larson AA, Baergen RN, Sommers RL, Kern S, Cavenee W. Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci using semi-automated fluorescence-based detection: subregional mapping of chromosome 4 in cervical carcinoma. Proc Natl Acad Sci U S A. 1996 Jun 25; 93(13):6704-9. PMID: 8692882; PMCID: PMC39090.
    180. Costello JF, Berger MS, Huang HS, Cavenee W. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 1996 May 15; 56(10):2405-10. PMID: 8625319.
      View in: PubMed
    181. Larson AA, Kern S, Sommers RL, Yokota J, Cavenee W, Hampton GM. Analysis of replication error (RER+) phenotypes in cervical carcinoma. Cancer Res. 1996 Mar 15; 56(6):1426-31. PMID: 8640835.
      View in: PubMed
    182. Besnard-Guérin C, Newsham I, Winqvist R, Cavenee W. A common region of loss of heterozygosity in Wilms' tumor and embryonal rhabdomyosarcoma distal to the D11S988 locus on chromosome 11p15.5. Hum Genet. 1996 Feb; 97(2):163-70. PMID: 8566947.
      View in: PubMed
    183. Furnari FB, Huang HJ, Cavenee W. Molecular biology of malignant degeneration of astrocytoma. Pediatr Neurosurg. 1996; 24(1):41-9. PMID: 8817614.
      View in: PubMed
    184. Bögler O, Huang HJ, Kleihues P, Cavenee W. The p53 gene and its role in human brain tumors. Glia. 1995 Nov; 15(3):308-27. PMID: 8586466.
      View in: PubMed
    185. Schwechheimer K, Huang S, Cavenee W. EGFR gene amplification--rearrangement in human glioblastomas. Int J Cancer. 1995 Jul 17; 62(2):145-8. PMID: 7622287.
      View in: PubMed
    186. Bögler O, Huang HJ, Cavenee W. Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. Cancer Res. 1995 Jul 01; 55(13):2746-51. PMID: 7796398.
      View in: PubMed
    187. Herbst RA, Larson A, Weiss J, Cavenee W, Hampton GM, Arden KC. A defined region of loss of heterozygosity at 11q23 in cutaneous malignant melanoma. Cancer Res. 1995 Jun 15; 55(12):2494-6. PMID: 7780954.
      View in: PubMed
    188. Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, Cavenee W, Kuerbitz SJ, Baylin SB. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med. 1995 Jun; 1(6):570-7. PMID: 7585125.
      View in: PubMed
    189. Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee W, Su Huang HJ. Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Res. 1995 May 01; 55(9):1941-5. PMID: 7728764.
      View in: PubMed
    190. Arap W, Nishikawa R, Furnari FB, Cavenee W, Huang HJ. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res. 1995 Mar 15; 55(6):1351-4. PMID: 7882335.
      View in: PubMed
    191. Cavenee W, White RL. The genetic basis of cancer. Sci Am. 1995 Mar; 272(3):72-9. PMID: 7871410.
      View in: PubMed
    192. Van Meir EG, Roemer K, Diserens AC, Kikuchi T, Rempel SA, Haas M, Huang HJ, Friedmann T, de Tribolet N, Cavenee W. Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells. Proc Natl Acad Sci U S A. 1995 Feb 14; 92(4):1008-12. PMID: 7862624; PMCID: PMC42626.
    193. Furnari FB, Huang HJ, Cavenee W. Genetics and malignant progression of human brain tumours. Cancer Surv. 1995; 25:233-75. PMID: 8718522.
      View in: PubMed
    194. Herbst RA, Nobori T, Cavenee W, Carson DA, Arden KC. Dinucleotide repeat polymorphism adjacent to CDKN2. Hum Mol Genet. 1994 Dec; 3(12):2265. PMID: 7881438.
      View in: PubMed
    195. Van Meir EG, Polverini PJ, Chazin VR, Su Huang HJ, de Tribolet N, Cavenee W. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet. 1994 Oct; 8(2):171-6. PMID: 7531056.
      View in: PubMed
    196. Hampton GM, Mannermaa A, Winqvist R, Alavaikko M, Blanco G, Taskinen PJ, Kiviniemi H, Newsham I, Cavenee W, Evans GA, Winquist R. Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res. 1994 Sep 01; 54(17):4586-9. PMID: 8062246.
      View in: PubMed
    197. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee W, Huang HJ. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A. 1994 Aug 02; 91(16):7727-31. PMID: 8052651; PMCID: PMC44475.
    198. Herbst RA, Weiss J, Ehnis A, Cavenee W, Arden KC. Loss of heterozygosity for 10q22-10qter in malignant melanoma progression. Cancer Res. 1994 Jun 15; 54(12):3111-4. PMID: 8205526.
      View in: PubMed
    199. Besnard-Guérin C, Cavenee W, Newsham I. A new highly polymorphic DNA restriction site marker in the 5' region of the human tyrosine hydroxylase gene (TH) detecting loss of heterozygosity in human embryonal rhabdomyosarcoma. Hum Genet. 1994 Mar; 93(3):349-50. PMID: 7510263.
      View in: PubMed
    200. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N, Cavenee W. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res. 1994 Feb 01; 54(3):649-52. PMID: 8306326.
      View in: PubMed
    201. Weiss J, Cavenee W, Herbst RA, Jung EG, Arden KC. Point mutations and allelic loss in the TP53 locus of cutaneous malignant melanomas. Arch Dermatol Res. 1994; 286(7):417-9. PMID: 7818283.
      View in: PubMed
    202. Weiss J, Rubinfeld B, Polakis PG, McCormick F, Cavenee W, Arden KC. The RAP1GA1 locus for human Rap1-GTPase activating protein 1 maps to chromosome 1p36.1-->p35. Cytogenet Cell Genet. 1994; 66(1):18-21. PMID: 8275700.
      View in: PubMed
    203. Karlbom AE, James CD, Boethius J, Cavenee W, Collins VP, Nordenskjöld M, Larsson C. Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet. 1993 Sep; 92(2):169-74. PMID: 8370584.
      View in: PubMed
    204. Weiss J, Schwechheimer K, Cavenee W, Herlyn M, Arden KC. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer. 1993 Jun 19; 54(4):693-9. PMID: 8514460.
      View in: PubMed
    205. Makos M, Nelkin BD, Chazin VR, Cavenee W, Brodeur GM, Baylin SB. DNA hypermethylation is associated with 17p allelic loss in neural tumors. Cancer Res. 1993 Jun 15; 53(12):2715-8. PMID: 8389241.
      View in: PubMed
    206. Schwechheimer K, Cavenee W. Genetics of cancer predisposition and progression. Clin Investig. 1993 Jun; 71(6):488-502. PMID: 8353410.
      View in: PubMed
    207. Rempel SA, Schwechheimer K, Davis RL, Cavenee W, Rosenblum ML. Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Cancer Res. 1993 May 15; 53(10 Suppl):2386-92. PMID: 8485725.
      View in: PubMed
    208. Kikuchi T, Rempel SA, Rutz HP, de Tribolet N, Mulligan L, Cavenee W, Jothy S, Leduy L, Van Meir EG. Turcot's syndrome of glioma and polyposis occurs in the absence of germ line mutations of exons 5 to 9 of the p53 gene. Cancer Res. 1993 Mar 01; 53(5):957-61. PMID: 8439970.
      View in: PubMed
    209. Cavenee W. A siren song from tumor cells. J Clin Invest. 1993 Jan; 91(1):3. PMID: 7678605; PMCID: PMC329986.
    210. Fong CT, White PS, Peterson K, Sapienza C, Cavenee W, Kern SE, Vogelstein B, Cantor AB, Look AT, Brodeur GM. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res. 1992 Apr 01; 52(7):1780-5. PMID: 1551108.
      View in: PubMed
    211. Loh WE, Scrable HJ, Livanos E, Arboleda MJ, Cavenee W, Oshimura M, Weissman BE. Human chromosome 11 contains two different growth suppressor genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci U S A. 1992 Mar 01; 89(5):1755-9. PMID: 1347425; PMCID: PMC48531.
    212. Tonin PN, Scrable H, Shimada H, Cavenee W. Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res. 1991 Oct 01; 51(19):5100-6. PMID: 1717137.
      View in: PubMed
    213. Ekstrand AJ, James CD, Cavenee W, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991 Apr 15; 51(8):2164-72. PMID: 2009534.
      View in: PubMed
    214. Cavenee W, Scrable HJ, James CD. Molecular genetics of human cancer predisposition and progression. Mutat Res. 1991 Apr; 247(2):199-202. PMID: 2011137.
      View in: PubMed
    215. James CD, He J, Carlbom E, Nordenskjold M, Cavenee W, Collins VP. Chromosome 9 deletion mapping reveals interferon alpha and interferon beta-1 gene deletions in human glial tumors. Cancer Res. 1991 Mar 15; 51(6):1684-8. PMID: 1998958.
      View in: PubMed
    216. Cavenee W, Ponder B, Solomon E. Genetics and cancer. Eur J Cancer. 1991; 27(12):1706-7. PMID: 1782088.
      View in: PubMed
    217. Houwen RH, Pautler SE, Barwell JA, Arden K, Buchanan JA, James CD, Cavenee W, Buys CH, Cowell JK, Cox DW. Isolation and regional localization of 25 anonymous DNA probes on a chromosome 13 hybrid panel. Cytogenet Cell Genet. 1991; 57(2-3):87-90. PMID: 1914527.
      View in: PubMed
    218. Cavenee W. Recessive mutations in cancer predisposition and progression. Basic Life Sci. 1991; 57:171-80; discussion 180-1. PMID: 1667571.
      View in: PubMed
    219. Hansen MF, Morgan R, Sandberg AA, Cavenee W. Structural alterations at the putative retinoblastoma locus in some human leukemias and preleukemia. Cancer Genet Cytogenet. 1990 Oct 01; 49(1):15-23. PMID: 2397469.
      View in: PubMed
    220. Gennett IN, Cavenee W. Molecular genetics in the pathology and diagnosis of retinoblastoma. Brain Pathol. 1990 Sep; 1(1):25-32. PMID: 1669690.
      View in: PubMed
    221. Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee W. Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci U S A. 1990 Aug; 87(15):5863-7. PMID: 2143022; PMCID: PMC54429.
    222. James CD, He J, Carlbom E, Mikkelsen T, Ridderheim PA, Cavenee W, Collins VP. Loss of genetic information in central nervous system tumors common to children and young adults. Genes Chromosomes Cancer. 1990 Jul; 2(2):94-102. PMID: 1980610.
      View in: PubMed
    223. Mikkelsen T, Cavenee W. Suppressors of the malignant phenotype. Cell Growth Differ. 1990 Apr; 1(4):201-7. PMID: 2128032.
      View in: PubMed
    224. Scrable HJ, Johnson DK, Rinchik EM, Cavenee W. Rhabdomyosarcoma-associated locus and MYOD1 are syntenic but separate loci on the short arm of human chromosome 11. Proc Natl Acad Sci U S A. 1990 Mar; 87(6):2182-6. PMID: 2315312; PMCID: PMC53650.
    225. Arden KC, Boutin JM, Djiane J, Kelly PA, Cavenee W. The receptors for prolactin and growth hormone are localized in the same region of human chromosome 5. Cytogenet Cell Genet. 1990; 53(2-3):161-5. PMID: 2369845.
      View in: PubMed
    226. James CD, Mikkelsen T, Cavenee W, Collins VP. Molecular genetic aspects of glial tumour evolution. Cancer Surv. 1990; 9(4):631-44. PMID: 1983210.
      View in: PubMed
    227. James CD, Carlbom E, Nordenskjold M, Collins VP, Cavenee W. Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sci U S A. 1989 Apr; 86(8):2858-62. PMID: 2565039; PMCID: PMC287018.
    228. Cavenee W, Hansen MF, Scrable HJ, James CD. Loss of genetic information in cancer. Ciba Found Symp. 1989; 142:79-88; discussion 88-92. PMID: 2743836.
      View in: PubMed
    229. Cavenee W. Tumor progression stage: specific losses of heterozygosity. Princess Takamatsu Symp. 1989; 20:33-42. PMID: 2488236.
      View in: PubMed
    230. Grundy P, Koufos A, Morgan K, Li FP, Meadows AT, Cavenee W. Familial predisposition to Wilms' tumour does not map to the short arm of chromosome 11. Nature. 1988 Nov 24; 336(6197):374-6. PMID: 2848199.
      View in: PubMed
    231. James CD, Carlbom E, Dumanski JP, Hansen M, Nordenskjold M, Collins VP, Cavenee W. Clonal genomic alterations in glioma malignancy stages. Cancer Res. 1988 Oct 01; 48(19):5546-51. PMID: 2901288.
      View in: PubMed
    232. Hansen MF, Cavenee W. Genetics of cancer predisposition. Cancer Res. 1987 Nov 01; 47(21):5518-27. PMID: 2889524.
      View in: PubMed
    233. Scrable HJ, Witte DP, Lampkin BC, Cavenee W. Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature. 1987 Oct 15-21; 329(6140):645-7. PMID: 3657988.
      View in: PubMed
    234. Buchanan JA, Cavenee W. Genetic markers for assessment of retinoblastoma predisposition. Dis Markers. 1987 Sep; 5(3):141-52. PMID: 3332257.
      View in: PubMed
    235. Gray A, Tam AW, Dull TJ, Hayflick J, Pintar J, Cavenee W, Koufos A, Ullrich A. Tissue-specific and developmentally regulated transcription of the insulin-like growth factor 2 gene. DNA. 1987 Aug; 6(4):283-95. PMID: 3652904.
      View in: PubMed
    236. Koufos A, Hansen MF, Copeland NG, Jenkins NA, Lampkin BC, Cavenee W. Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature. 1985 Jul 25-31; 316(6026):330-4. PMID: 2991766.
      View in: PubMed
    237. Koufos A, Hansen MF, Lampkin BC, Workman ML, Copeland NG, Jenkins NA, Cavenee W. Loss of alleles at loci on human chromosome 11 during genesis of Wilms' tumour. Nature. 1984 May 10-16; 309(5964):170-2. PMID: 6325936.
      View in: PubMed